Processa Pharmaceuticals, Inc. Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Expense
Processa Pharmaceuticals, Inc. (PCSA) reported Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Expense of -$1.73 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-09-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for the quarter ending 2016-12-31 was $17.00, a 99.98% decline year-over-year.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for the quarter ending 2016-09-30 was $42.00, a 99.94% decline year-over-year.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for the quarter ending 2016-06-30 was $48.00, a 99.96% decline year-over-year.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for the quarter ending 2016-03-31 was $2.00K, a 98.76% decline year-over-year.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for fiscal 2016 was -$1.73K, a 100.43% decline from fiscal 2015.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for fiscal 2015 was $400.18K, a 57.14% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, expense for fiscal 2014 was $933.61K.
| Period end | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Expense 3 month | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Expense 6 month | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Expense 9 month | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Expense 12 month |
|---|---|---|---|---|
| 2016-12-31 | $17.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $59.00 derived: sum of 2 quarters · filed 2017-11-20 | $107.00 derived: sum of 3 quarters · filed 2017-11-20 | -$1.73K 10-K · filed 2017-09-25 |
| 2016-09-30 | $42.00 10-Q · filed 2017-11-20 | $90.00 derived: sum of 2 quarters · filed 2017-11-20 | -$1.75K 10-Q · filed 2017-11-20 | $71.02K derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | $48.00 10-Q · filed 2017-10-04 | -$1.79K 10-Q · filed 2017-10-04 | $70.98K derived: sum of 3 quarters · filed 2017-10-04 | $136.56K derived: sum of 4 quarters · filed 2017-10-04 |
| 2016-03-31 | $2.00K 10-Q · filed 2017-10-04 | $70.93K derived: sum of 2 quarters · filed 2017-10-04 | $136.51K derived: sum of 3 quarters · filed 2017-10-04 | $252.71K derived: sum of 4 quarters · filed 2017-10-04 |
| 2015-12-31 | $68.93K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $134.51K derived: sum of 2 quarters · filed 2017-09-25 | $250.71K derived: sum of 3 quarters · filed 2017-09-25 | $400.18K 10-K · filed 2017-09-25 |
| 2015-09-30 | $65.58K 10-Q · filed 2017-09-08 | $181.78K derived: sum of 2 quarters · filed 2017-09-08 | $331.25K 10-Q · filed 2017-09-08 | |
| 2015-06-30 | $116.20K 10-Q · filed 2017-08-30 | $225.09K 10-Q · filed 2017-08-30 | ||
| 2015-03-31 | $161.01K 10-Q · filed 2017-08-07 | |||
| 2014-12-31 | $933.61K 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |